Who Optimizes SG&A Costs Better? AstraZeneca PLC or Sarepta Therapeutics, Inc.

AstraZeneca vs. Sarepta: A Tale of SG&A Optimization

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, AstraZeneca PLC and Sarepta Therapeutics, Inc. have shown contrasting approaches to SG&A cost management. AstraZeneca, a global leader, has consistently maintained high SG&A expenses, peaking at approximately $18 billion in 2022. This reflects their expansive global operations and extensive marketing efforts. In contrast, Sarepta, a smaller biotech firm, has kept its SG&A costs significantly lower, with a peak of around $482 million in 2023. This stark difference highlights AstraZeneca's broad market reach compared to Sarepta's focused niche strategy. Over the years, AstraZeneca's SG&A expenses have grown by about 35%, while Sarepta's have surged by nearly 900%, indicating rapid expansion. This data provides a fascinating insight into how two companies navigate the financial landscape of the pharmaceutical industry.

Short Description

"AstraZeneca vs. Sarepta: SG&A Cost Strategies Unveiled"